Real‐World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: A Propensity‐Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis

In this propensity-weighted registry analysis, triplet therapy was not demonstrably superior to ARPI-based doublet therapy for time to CRPC. Exploratory Bayesian synthesis suggests a modest CRPC-free RMST advantage with triplet therapy, but inferences depend on external evidence and remain hypothesis-generating.